Oppenheimer Maintains Outperform on PDS Biotechnology, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell has maintained an Outperform rating on PDS Biotechnology (NASDAQ:PDSB) but has reduced the price target from $23 to $20.
November 15, 2023 | 6:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer analyst Leland Gershell maintains an Outperform rating on PDS Biotechnology but lowers the price target from $23 to $20.
While the reduction in price target could suggest a tempered expectation for PDS Biotechnology's stock performance, the maintenance of an Outperform rating indicates that the analyst still has a positive outlook on the company's prospects. This mixed signal may lead to a neutral short-term impact on the stock price as investors weigh the lower price target against the continued positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100